Latest funding news
Following the news that the NIHR funding for our Cochrane Review Group was being withdrawn after 31 March 2023, we have endeavoured to find alternative funding sources. It is with great pleasure that we can announce that we have been successful in obtaining funding to continue with a programme of CF reviews and evidence syntheses to support guidelines and share this information with our CF community. More details will follow, but at this point we would like to document our gratitude to the CF Foundation and the UK CF Trust for awarding us this grant. We are looking forward to working with them closely over the next two years.
Our joy at this success is tempered by the fact that we will no longer be able to support our reviews and authors in the other areas of our scope, namely haemoglobinopathies, coagulopathies and inborn errors of metabolism. We would like to thank all our editors, authors, peer reviewers and consumers in these areas of our scope for their contribution to the Group’s success to date. We would not have been able to achieve this without your enthusiasm and dedication. From now on, From now on, Cochrane will be assessing all proposals, protocols, reviews, and updates centrally. Please contact email@example.com if you have any questions regarding new or updated reviews.
Standards of care for CFTR variant-specific therapy for people with CF published
We are proud to announce that four of our CF editors and several more of our Group’s contributors, supported by the European Cystic Fibrosis Society, have written and published detailed standards of care for CFTR variant-specific therapy (including modulators) for people with CF. The recently published paper is freely available to access here.
In recent years, therapy tailored to specific variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene has transformed the management of CF and consequently the lives of people living with CF. Taken orally, variant-specific therapy corrects the molecular defect that causes the condition, rather than treating the clinical issues resulting from the condition; thus a relatively simple treatment can greatly ease the treatment burden for those people with CF whose genetic variants can be treated with this therapy. This is still an emerging area of research, but the CFGD Group’s up-to-date Cochrane Reviews underpin the new evidence-based pragmatic guidance for people with CF and their CF teams. The paper also highlights the importance of continued standard treatment for those whose genotypes are as yet ineligible for variant-specific therapy and of continued research to identify and develop therapy for those genotypes.
Cochrane invites prospective authors to propose new Cochrane Reviews by submitting a proposal in Editorial Manager. Please see the Cochrane Library information for authors for further details.
|Latest output published on The Cochrane Library|
|On Issue 10 2022 of The Cochrane Library we have published a total of 199 reviews and 27 protocols. The production of these reviews involves a network of over 1000 contributors (authors, consumers and referees) throughout the world. We very much welcome interest from new consumers, referees and potential reviewers. Further information can be obtained by contacting the group.|
By getting involved in these priority-setting partnerships you can help shape future research.
We have already successfully been involved in a priority-setting partnership for CF and you can see the results here. A second iteration of this is now underway.
A priority-setting partnership has also been undertaken in bleeding disorders; more information can be found here.